• Add this page to "Favorite pages"
  • Print the text(Open link in a new browser window)
Here begins the text.

Subcommittee on Therapeutic Products Based on Extracellular Vesicles (EVs) Including Exosomes

Background

Extracellular Vesicles (EVs), such as exosomes, are thought to be responsible for intercellular communication through the functional molecules they contain. Since it has been reported that EVs cause some of the paracrine effects of mesenchymal stem cells (MSCs) which have tissue repair properties, the practical use of EVs secreted by MSCs derived from bone marrow, adipose, or umbilical cord is expected as a notable next-generation therapeutic tool without using cells.
The subcommittee discusses evaluation of safety against viruses and other infectious factors, quality characterization of active ingredients, ensuring consistency in manufacturing, manufacturing process control, evaluation strategies for non-clinical studies, and points to consider in clinical trials.
 

Member List

Member List of the Subcommittee on Therapeutic Products Based on Extracellular Vesicles (EVs) Including Exosomes

Past meetings

Date No. PressRelease Agenda/List of Handouts Minutes
September 22, 2022 6th mtg. PressRelease Agenda/List of Handouts Minutes
June 20, 2022 5th mtg. PressRelease Agenda/List of Handouts Minutes
March 30, 2022 4th mtg. PressRelease Agenda/List of Handouts Minutes
January 17, 2022 3rd mtg. PressRelease Agenda/List of Handouts Minutes
October 4, 2021 2nd mtg. PressRelease Agenda/List of Handouts Minutes
August 4, 2021 1st mtg. PressRelease Agenda/List of Handouts Minutes

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

  • Contact us
  • Access/Map

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.